Abstract：
Sugammadex is a distinctive neuromuscular reversal drug that acts by encapsulating the neuromuscular relaxant molecule and dislodging it from its site of action. Sugammadex has been approved for pediatric patients over 2 years of age. Although arrhythmias have been reported, there is no report of adverse effects in healthy children, such as severe bradycardia requiring intervention. We report two cases of severe bradycardia immediately after the administration of sugammadex in healthy children. Our aim is to alert to the occurrence of one of the most severe adverse effects of sugammadex, in the healthy pediatric population as well.
摘要：
Sugammadex是一种独特的神经肌肉逆转药物，通过封装神经肌肉松弛剂分子并将其从其作用部位移出。Sugammadex已被批准用于2岁以上的儿科患者。尽管已经报道了心律失常，健康儿童没有不良反应的报告，如严重的心动过缓需要干预。我们报告了健康儿童服用sugammadex后立即发生的两例严重心动过缓。我们的目的是警惕sugammadex最严重的不良反应之一的发生，在健康的儿科人群中也是如此。
